Overview

Clinical Trial for the Prevention of Vasovagal Syncope

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
Phase:
Phase 4
Details
Lead Sponsor:
University of Calgary
Collaborator:
Canadian Institutes of Health Research (CIHR)
Treatments:
Fludrocortisone